RAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare Conference

Rhea-AI Summary

RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that CEO Brian Wong will present at the 2021 Cantor Virtual Healthcare Conference on September 27, 2021, at 2:00 p.m. EST. The company focuses on developing oral small molecule therapies for unmet needs in oncology and inflammatory diseases, with two drug candidates, FLX475 and RPT193, targeting CCR4 receptors. For access to the live webcast and archived recordings, visit the RAPT Therapeutics website.

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the 2021 Cantor Virtual Healthcare Conference on Monday, September 27, 2021 at 2:00 p.m. EST.

To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com

RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com 

FAQ

What is the date and time of RAPT's presentation at the Cantor Virtual Healthcare Conference?

RAPT's presentation at the Cantor Virtual Healthcare Conference is scheduled for September 27, 2021, at 2:00 p.m. EST.

Who will present for RAPT Therapeutics at the Cantor Conference?

Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics, will present at the conference.

Where can I watch the RAPT Therapeutics presentation?

You can access the live webcast and archived presentation on the RAPT Therapeutics website.

What are the main focuses of RAPT Therapeutics?

RAPT Therapeutics focuses on discovering and developing oral small molecule therapies for oncology and inflammatory diseases.

What drug candidates is RAPT currently developing?

RAPT is developing FLX475 and RPT193, both targeting the CCR4 receptor for treatment in cancer and inflammation.